Skip to main content

Table 1 Demographic and clinical characteristics of 63 individuals recruited classified in 3 groups.

From: Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension

  Group ofCOPD+PAH (n = 12) Group of COPD (n = 36) Group of HS (n = 15)
Sex, M/F 11/1 32/4 9/6
Age, Years 70.8 (6.7) 67.6 (9.2) 58 (9.2)
Smoking, pack-years 27 (7) 25 (6) 0
FEV1% 39.35 (11.45) 48.13 (18.04) 98.05 (11.65)
FVC% 64.89 (14.90) 69.39 (19.1) 95.07 (13.34)
FEV1/FVC % 46.95 (6.81) 54.27 (12.46) 101.37 (8.5)
RV% 151 (38) 143 (32) 108 (11)
PaO2 (mmHg) 60.83 (4.76) 64.58 (6.16) 97.2 (0.7)
PaCO2 (mmHg) 39.4 (4.27) 41.78 (5.01) 38.4 (1.5)
PaPs (mmHg) 51.08 (12.2)* 26.05 (3.39) NA
ET-1 EBC (pg/ml) 22.36 (4) 7.25 (0.23) 5.24 (0.47)
ET-1 art (pg/ml) 12.41 (2.13) 7.22 (0.21) 0.84 (0.37)
ET-1 ven (pg/ml) 14.53 (2.76) 7.29 (0.16) 1 (0.42)
FENO (ppb) 22.92 (11.38) 35.07 (17.53) 20.56 (3.67)
6MWD 383 (34)§ NA NA
  1. Pulmonary function, arterial blood gases, pulmonary-artery systolic pressure, exhaled breath condensate counts and circulating levels are expressed in table 1. Statistical significant difference was found between groups 1 and 2 in pulmonary-artery systolic pressure, PaPs (p < 0.0001).
  2. Definition of abbreviations
  3. EBC: Exhaled Breath Condensate, ET-1: Endothelin-1, FENO: Exhaled Nitric Oxide, FEV1: Forced Expiratory Volume in the first second, FVC: Forced Vital Capacity, HS: Healthy Subjects, NO: Nitric Oxide, PAH: Pulmonary Artery Hypertension, RV: Residual Volume, PaPs: Pulmonary-artery systolic pressure, 6MWD: 6-minutes walking distance
  4. Data are presented as mean (± SD)
  5. NA = not applicable
  6. § n = 6 patients
  7. * Significant difference compared to COPD group: p < 0.001